Connection
Douglas Ney to Prognosis
This is a "connection" page, showing publications Douglas Ney has written about Prognosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.134 |
|
|
|
-
Ney DE, Carlson JA, Damek DM, Gaspar LE, Kavanagh BD, Kleinschmidt-DeMasters BK, Waziri AE, Lillehei KO, Reddy K, Chen C. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. J Neurooncol. 2015 Mar; 122(1):135-43.
Score: 0.070
-
Ney DE, Lassman AB. Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directions. Curr Oncol Rep. 2009 Jan; 11(1):62-7.
Score: 0.046
-
Carlson JA, Reddy K, Gaspar LE, Ney D, Kavanagh BD, Damek D, Lillehei K, Chen C. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. J Neurooncol. 2015 Jun; 123(2):251-7.
Score: 0.018